ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

BLGO BioLargo Inc (QB)

0.35
0.00505 (1.46%)
06 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
BioLargo Inc (QB) USOTC:BLGO OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00505 1.46% 0.35 0.3401 0.3697 0.35 0.33 0.345 167,587 21:15:14

Statement of Changes in Beneficial Ownership (4)

05/05/2020 9:41pm

Edgar (US Regulatory)


FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

PROVENZANO JOSEPH L
2. Issuer Name and Ticker or Trading Symbol

BIOLARGO, INC. [ BLGO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Secretary
(Last)          (First)          (Middle)

14921 CHESTNUT ST.
3. Date of Earliest Transaction (MM/DD/YYYY)

5/1/2020
(Street)

WESTMINSTER, CA 92683
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option to purchase common stock $0.14 5/1/2020  A   50000    5/1/2020 5/1/2030 Common stock 50000 $0 (1)1678703 (2)D  
Option to purchase common stock $0.14 5/1/2020  A   202110    8/1/2020 (4)5/1/2030 Common stock 202110 $0 (3)1880813 D  

Explanation of Responses:
(1) This Option was granted to Reporting Person to replace an option to purchase 200,000 shares that had been issued approximately 10 years ago to compensate Reporting Person for services to the Issuer and had recently expired unexercised due to a discrepancy between the original exercise price and current Issuer stock price, pursuant to plan adopted by the Issuer's Compensation Committee.
(2) This amount reflects, in addition to the reported option grant, the expiration on February 1, 2020, of an option to purchase 200,000 shares of common stock.
(3) On May 1, 2020, in recognition of recent accomplishments in response to the COVID-19 pandemic, the Issuer's Compensation Committee granted options to the Issuer's employees under the 2018 Equity Incentive Plan, including the option reported herein.
(4) This option vests in four equal installments every three months beginning August 1, 2020.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
PROVENZANO JOSEPH L
14921 CHESTNUT ST.
WESTMINSTER, CA 92683
X
Secretary

Signatures
/s/ John R. Browning, Attorney-in-fact5/5/2020
**Signature of Reporting PersonDate

1 Year BioLargo (QB) Chart

1 Year BioLargo (QB) Chart

1 Month BioLargo (QB) Chart

1 Month BioLargo (QB) Chart

Your Recent History

Delayed Upgrade Clock